Background: Data on long-term topical sirolimus treatment of the cutaneous manifestations of tuberous sclerosis complex are rare.
Objective: To evaluate the long-term benefit and tolerance of topical 1% sirolimus in tuberous sclerosis complex.
Methods: In this 18-month prospective single-center study, 1% sirolimus cream was applied daily to facial angiofibromas (FAs), fibrous cephalic plaques (FCPs), shagreen patches, hypomelanotic macules, and ungual fibromas. After complete clearance (CC) of FAs, we evaluated a maintenance protocol of 3 applications weekly.
Results: Twenty-five patients were enrolled. Fifty percent obtained CC of FAs within 9 months. Of 7 patients with CC (58%) who were following the maintenance protocol, 6 relapsed within 7 months and 1 was still responding at 1 year. Of 16 patients with FCPs, 7 (44%) remained stable at 12 months and 9 (56%) improved after 3 to 9 months of treatment. Only 1 of 5 patients treated for shagreen patches showed improvement at 12 months. Treatment was well tolerated with no serious adverse events.
Limitations: The small number of patients was a limitation.
Conclusions: Topical 1% sirolimus applied daily produced positive responses in treatment of FAs, FCPs, and facial hypomelanotic macules and was well tolerated. A 3-times-weekly maintenance protocol did not prevent FA relapses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2017.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tuberous sclerosis: a survey in the canton of Vaud, Switzerland.
Front Med (Lausanne)
December 2024
Department of Medicine, Service of Nephrology, Fribourg State Hospital, Fribourg, Switzerland.
Aim Of The Study: Tuberous sclerosis complex (TSC) is a genetic and multisystemic disorder that affects between 1/6'000 and 1/10'000 of newborns. Clinical criteria and/or genetic analysis establish the diagnosis. The mechanistic target of rapamycin (mTOR) inhibitors everolimus or sirolimus reduce the severity of several TSC-related clinical traits.
View Article and Find Full Text PDFSelective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow.
J Am Acad Dermatol
December 2024
Department of Dermatology, University of Minnesota, Minneapolis, Minnesota; Department of Medicine, University of Minnesota, Minneapolis, Minnesota; Departments of Medicine and Dermatology, Minneapolis VA Health Care System, Minneapolis, Minnesota. Electronic address:
Hidradenitis suppurativa (HS) is an autoinflammatory condition characterized by abscesses, inflammatory nodules, and tunnels in intertriginous sites of the body. The pathogenesis of HS involves follicular occlusion in combination with environmental, genetic, hormonal, and metabolic factors. HS lesions are characterized by an influx of neutrophils, histiocytes, B and T cells, and upregulation of proinflammatory cytokines such as tumor necrosis factor-α, interleukin-1, interleukin-17, and interferons.
View Article and Find Full Text PDFTrial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients.
Trials
November 2024
Frazer Institute, The University of Queensland, Experimental Dermatology Group, Brisbane, Australia.
Article Synopsis
- Keratinocyte carcinomas, like basal and squamous cell carcinomas, are common and serious issues for solid organ transplant recipients, necessitating early detection and effective treatment strategies.
- A Phase III clinical trial, called the SiroSkin trial, will assess the effectiveness of topical sirolimus in reducing skin cancer incidence among these patients compared to a placebo, involving 146 participants over 24 weeks of treatment and 18 months of follow-up.
- The trial's results aim to enhance management approaches for skin cancers in solid organ transplant recipients and gather evidence on the cost-effectiveness of using topical sirolimus.
Scanning Transmission Soft X-Ray Microscopy Probes Topical Drug Delivery of Rapamycin Facilitated by Microneedles.
Chemphyschem
January 2025
Physikalische Chemie, Freie Universität Berlin, Arnimallee 22, 14195, Berlin, Germany.
Scanning Transmission X-ray microscopy (STXM) is a sensitive and selective probe for the penetration of rapamycin which is topically applied to human skin ex vivo and is facilitated by skin treatment with microneedles puncturing the skin. Inner-shell excitation serves as a selective probe for detecting rapamycin by changes in optical density as well as linear combination modeling using reference spectra of the most abundant species. The results indicate that mechanical damage induced by microneedles allows this drug to accumulate in the stratum corneum without reaching the viable skin layers.
View Article and Find Full Text PDFCutaneous Collagenous Vasculopathy: A Retrospective Clinical and Histopathologic Analysis of 34 Cases.
J Cutan Med Surg
November 2024
Department of Dermatology, Mayo Clinic Florida, Jacksonville, FL, USA.
Background: Cutaneous collagenous vasculopathy (CCV) is a rare acquired microangiopathy that commonly affects middle-aged, fair-skinned individuals. It presents with telangiectatic lesions involving the lower extremities. Histologic analysis is mandatory for diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!